MALVERN, PA — KPS Life, LLC recently announced the completion of a growth capital raise from LongueVue Capital and Adrian Otte. LongueVue Capital is an operator-centric, New Orleans-based equity fund with ~$500 million under management. Adrian, LVC’s Life Sciences Operating Partner and seasoned pharma executive, invested alongside LVC in the transaction and will serve on the Company’s Board of Directors moving forward.
Headquartered in Malvern, PA, KPS is a functional service provider (“FSP”) that offers global functional clinical trial outsourcing services to sponsors. Its services include clinical monitoring, clinical oversight, clinical trial management, data management, eTMF and document management, vendor qualification, and medical writing. Founded in 2006, KPS has carved out a leadership position within the FSP market by providing high-quality and customized clinical trial execution while mitigating costs and increasing transparency for its clients. The Company’s operations span six continents and more than 20 countries, supporting pharmaceutical and biotech companies of all sizes across all stages of clinical trials.
“KPS is extremely excited to work with LongueVue Capital and Adrian Otte. We were looking for a strategic partner who could provide not just capital, but also the resources to help us drive outsized growth without sacrificing our high touchpoint customer service model. We found that partner in LongueVue,” said David Kelly, CEO of KPS. “We are impressed by LVC’s deep industry relationships and proven track record of growing middle-market businesses at inflection points. Their expertise within the healthcare sector – and specifically life sciences – was apparent during our diligence process.” David added, “We view Adrian as an extension of our team, and he will be invaluable to our organization and customers. We look forward to working closely together with LVC and Adrian to build upon our success to date.”
“I am a strong proponent of the FSP model and a firm believer in the capabilities of the KPS team,” added Adrian. “After transitioning numerous operations to the FSP model over my 30+ year career, I believe the benefits for sponsors of the FSP model over the full-service clinical research outsourcing model remain substantial. I am confident KPS is well-positioned to capitalize on increasing FSP spend, and I am excited to work actively with the KPS team and its customers to enhance existing offerings and drive sustainable growth.”
“Despite COVID-19 and the challenging backdrop of 2020, KPS realized meaningful growth with both new and existing customers, exemplifying the Company’s mission-critical services and strong value proposition,” said Ryan Nagim, Partner at LVC. “We see a unique opportunity to draw upon Adrian’s background in the clinical development space to further accelerate the Company’s growth as value-added partners.”
Adrian recently joined the LVC team as an Operating Partner to support the firm’s Healthcare and Life Sciences investment strategy. Previously, Adrian held various senior leadership positions with both pharmaceutical and services companies, including serving as Vice President of Global Development Operations at Amgen, Senior Vice President of Global Development Operations at Pfizer, Chief Operating Officer at ICSL Healthcare Research (sold to Comprehensive Neuroscience), Vice President of Medical Research at AstraZeneca, and Senior Vice President of Research Operations at Parexel.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.